Granules India, a pharmaceutical company, has announced a $400 million investment over the next two years to backward integrate its major products and establish a greenfield formulation plant near Hyderabad. The business’s managing director, Krishna Prasad Chigurupati, told ET that the company has begun work on end-to-end manufacture of at least two critical large-volume compounds.
According to Prasad, the backward integration will help Granules to reduce supply chain interruptions, pricing volatility, and raise environmental standards expectations.
Granules plans to invest roughly Rs. 250 crore in backward integration and Rs. 150 crore in a new formulation manufacturing facility in Genome Valley, near Hyderabad.
